Supplementary material

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient

Cancer Chemotherapy and Pharmacology

Julia Schäfer\textsuperscript{a}, Lukas Welti\textsuperscript{a}, Anja Seckinger\textsuperscript{b}, Jürgen Burhenne\textsuperscript{a}, Dirk Theile\textsuperscript{a#}, Johanna Weiss\textsuperscript{a*#}

a) Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

b) Department of Internal Medicine V, Oncology, Hematology, and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

\# Contributed equally

*) Corresponding author

Prof. Johanna Weiss, PhD

Phone: +49 6221 56 39402, Fax: +49 6221 56 4642

Email address: johanna.weiss@med.uni-heidelberg.de
**Fig.**: Correlation of intracellular concentration of unbound carfilzomib (CFZ) [nM] with proteasomal subunit activities 1 h after starting the exposure to 10 nM CFZ. Spearman test showed a trend for negative correlation \((r = -0.6905, p = 0.0694)\) between chymotrypsin-like subunit (a) activity and intracellular unbound CFZ concentration.